Samsca Liver Injury Warning Issued By FDA

Irvin Jackson

Add Your Comments

Federal drug experts are placing a one month limit on the recommended use of Samsca, a hyponatremia drug that has been linked to a risk of liver damage.  

The FDA issued a drug safety communication (PDF) on April 30, indicating that Samsca should not be used for longer than 30 days. The agency also warned that the drug should not be used in patients with underlying liver disease.

Samsca side effects have been associated with a potential risk of severe liver injury, which could result in the need for a liver transplant or death, according to the warning.

Do You Know about…

Spinal Cord Stimulator lawsuits

Spinal cord stimulator lawsuits are being investigated for individuals who suffered unnecessary shocks, burns or other problems, often resulting in the need for additional surgery to remove the SCS.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION
Spinal-Cord-Stimulation-Lawsuit
Spinal-Cord-Stimulation-Lawsuit

Do You Know About…

Spinal Cord Stimulator lawsuits

Spinal cord stimulator lawsuits are being investigated for individuals who suffered unnecessary shocks, burns or other problems, often resulting in the need for additional surgery to remove the SCS.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION

Along with the announcement, the FDA announced that it is updating the Samsca warning label to included a 30 day limit on use, the contraindication for patients with liver disease, and descriptions of liver problems from Samsca seen during clinical trials. The label will also recommend that doctors discontinue use when a patient shows signs of liver injury.

Samsca (tolvaptan) is an Otsuka Pharmaceutical Co. drug approved for the treatment of clinically significant hypervolemic and euvolemic hyponatremia, a condition that results in critically low salt levels. It belongs to a family of drugs known as selective vasopressin V2-receptor antagonists.

There have been about 16,000 prescriptions for Samsca since it was approved in May 2009.

The FDA began looking at the drug’s safety profile after Otsuka sent out a Dear Healthcare Provider letter (PDF) on January 22, warning that Samsca liver injury could be permanent and fatal. The letter came after three clinical trial patients suffered liver damage while taking the drug. All three recovered after they stopped taking Samsca.

The FDA now believes that Samsca can cause serious and fatal liver injury. The agency warned doctors to look for signs of liver injury among patients taking Samsca. Samsca patients should talk to their doctor if they experience:

  • Loss of appetite
  •  Nausea or vomiting
  •  Fever
  •  Unusual fatigue
  •  Itching
  •  Yellowing of the skin or eyes
  •  Unusually dark urine
  •  Pain in the right upper abdomen
Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.

Tags: Liver Damage, Liver Injury, Otsuka Pharmaceutical Co, Samsca

More Lawsuit Stories

0 Comments

This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Medtronic SCS Lawsuit Alleges Intellis LT Neurostimulator Caused Worsening Pain
An Illinois woman has joined a growing number of plaintiffs alleging that the Medtronic Intellis neurostimulator, and similar devices, may fail to relieve chronic pain and instead lead to worsening complications.
Court Outlines Plan To Prepare Suboxone Tooth Decay Lawsuits for Trial in Early 2028
Four Suboxone tooth decay lawsuits will eventually be selected and prepared for bellwether trials set to begin in March 2028, according to a court order.
Hair Relaxer Class Action Lawsuit Certification Sought For Medical Monitoring Claims
A federal judge is being asked to certify seven hair relaxer class action lawsuits seeking medical monitoring for users, following studies that link the products to an increased risk of cancer.